Abstract
The application of antiangiogenic agents in cancer therapy has been studied extensively. Combination of agents with antiangiogenic properties could possibly enhance antitumor effects. Interleukin 12 is a cytokine with potent antitumor activity mediated also via antiangiogenic mechanisms. These effects are attributed to IFN-γ production stimulated by IL-12. Since IFN-γ has been reported to augment antitumor effects when combined with one of the metalloproteinase inhibitors - batimastat (BB-94), we have examined a combined treatment with IL-12 and BB-94 in a murine melanoma model. The administration of both agents showed potentiated antitumor activity. Furthermore, we have shown in a tumor-induced angiogenesis model that the combined application of IL-12 and batimastat inhibits the formation of new blood vessels to a greater extent than either agent alone. Our observations show that antiangiogenic effects are at least partly responsible for the enhanced antitumor effects of the combined treatment with IL-12 and BB-94.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 391-394 |
| Number of pages | 4 |
| Journal | Anticancer Research |
| Volume | 20 |
| Issue number | 1 A |
| State | Published - 2000 |
| Externally published | Yes |
Keywords
- Angiogenesis
- Batismatat metalloproteinase inhibitor
- Interleukin 12
- Melanoma
- Mice
ASJC Scopus subject areas
- Oncology
- Cancer Research